RxDoctor Payments DataLook up a doctor →

Jason Taylor, MD

Rheumatology · Madison, MSNPI 1649481607

Payments from drug & device makers

$173,016in general payments, 2019–2025

Across 1,366 payments — averaging $126.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$82K
  • Novartis$23K
  • Amgen$16K
  • Mallinckrodt Enterprises LLC$13K
  • Mallinckrodt Hospital Products Inc.$11K
  • Pfizer$10K
  • plus $18K from 22 others

What the payments were for

  • Consulting fees$12,5657%
  • Speaking & faculty fees$133,28977%
  • Travel & lodging$5,2133%
  • Food & beverage$21,76013%
  • Education$1900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,016 in reported general payments places this provider in the 90th percentile of 44 rheumatology providers in Mississippi.

See all rheumatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$188,145
Medicare patients
622
Services billed
6,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab129$955,335
Enbrel SureclickEtanercept96$697,120
RinvoqUpadacitinib73$452,800
Enbrel MiniEtanercept40$296,055
Orencia ClickjectAbatacept49$276,300
Xeljanz XrTofacitinib Citrate40$220,502
Simponi AriaGolimumab17$157,016
Cimzia (2 Pack)Certolizumab Pegol26$150,474
SimponiGolimumab22$149,017
HumiraAdalimumab15$106,955
OrenciaAbatacept/Maltose18$91,506
Cosentyx Sensoready (2 Pens)Secukinumab11$79,061
Actemra ActpenTocilizumab12$55,667
ForteoTeriparatide12$50,652
Hydroxychloroquine Sulfate800$34,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$82,265$559,75488 claims
Johnson & JohnsonSimponi Aria, Simponi$6,771$306,03439 claims
UCB, Inc.Cimzia (2 Pack)$640$150,47426 claims
E.r. Squibb & Sons, L.L.C.Orencia$542$91,50618 claims
Lilly USA, LLCForteo$444$50,65212 claims
AmgenProlia$16,419$22,65413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 rheumatology providers in Mississippi.

Other rheumatology in Madison

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →